Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV5PEK)

Drug Name

ARO-HIF2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HIF2-alpha messenger RNA (EPAS1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PT2385	DMCSN69	Recurrent glioblastoma	2A00.00	Phase 2	[3]
ISIS 222041	DMS03TR	Discovery agent	N.A.	Investigative	[4]
ISIS 222035	DMQY2EA	Discovery agent	N.A.	Investigative	[4]
ISIS 222039	DMVL1SN	Discovery agent	N.A.	Investigative	[4]
ISIS 222001	DMD7HA3	Discovery agent	N.A.	Investigative	[4]
ISIS 222043	DM26M7E	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HIF2-alpha messenger RNA (EPAS1 mRNA)	TTWPA54	EPAS1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04169711) Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma. U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug name ARO-HIF2).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.